These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17369583)

  • 1. KIT mutations and imatinib dose effects in patients with gastrointestinal stromal tumors.
    De Giorgi U
    J Clin Oncol; 2007 Mar; 25(9):1146-7; author reply 1147-8. PubMed ID: 17369583
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F; Detken S; Schulten HJ; Happel N; Gunawan B; Kuhlgatz J; Füzesi L
    Ann Surg Oncol; 2007 Feb; 14(2):526-32. PubMed ID: 17139461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
    Patel S; Zalcberg JR
    Eur J Cancer; 2008 Mar; 44(4):501-9. PubMed ID: 18234488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
    Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S
    Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916
    [No Abstract]   [Full Text] [Related]  

  • 7. [A step foward in the treatment of GIST].
    Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(4):223-4. PubMed ID: 18776977
    [No Abstract]   [Full Text] [Related]  

  • 8. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML
    Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on the mechanism of imatinib-induced resistance in gastrointestinal stromal tumors].
    Zhou Y; Hou YY; Tan YS; Lu SH; Hou J; Liu JL; Qin J; Shen KT; Sun YH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):597-601. PubMed ID: 20021947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
    Gronchi A; Blay JY; Trent JC
    Cancer; 2010 Apr; 116(8):1847-58. PubMed ID: 20166214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Kim HC; Kim KH; Yook JH; Kim BS; Kang YK
    J Surg Oncol; 2008 Jul; 98(1):27-33. PubMed ID: 18452195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA updates Gleevec label for GIST patients.
    Schmidt C
    J Natl Cancer Inst; 2012 Mar; 104(5):346. PubMed ID: 22349200
    [No Abstract]   [Full Text] [Related]  

  • 16. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate.
    Sciot R; Debiec-Rychter M; Daugaard S; Fisher C; Collin F; van Glabbeke M; Verweij J; Blay JY; Hogendoorn PC; ; ;
    Eur J Cancer; 2008 Sep; 44(13):1855-60. PubMed ID: 18653326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
    Judson I
    Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of recurrent GIST successfully treated with low-dose imatinib mesilate].
    Hanada N; Kawamura Y; Taneda T; Yoshida Y; Osako T; Inoue K
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):799-801. PubMed ID: 16770100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.
    Loughrey MB; Beshay V; Dobrovic A; Zalcberg J; Waring PM
    Histopathology; 2006 Jul; 49(1):99-100. PubMed ID: 16842259
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of c-kit mutation on the prognosis of gastrointestinal stromal tumors: a meta-analysis].
    Zhao WY; Cao H; Zhang Y; Shen ZY; Wu ZY
    Zhonghua Wai Ke Za Zhi; 2009 Jun; 47(11):857-62. PubMed ID: 19961019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.